A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

NCT05912296 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipemia

Interventions

DRUG: RBD7022
DRUG: RBD7022
DRUG: Placebo
DRUG: Placebo

Sponsor

Suzhou Ribo Life Science Co. Ltd.